MX2020000636A - Proteinas sinteticas y usos terapeuticos de las mismas. - Google Patents
Proteinas sinteticas y usos terapeuticos de las mismas.Info
- Publication number
- MX2020000636A MX2020000636A MX2020000636A MX2020000636A MX2020000636A MX 2020000636 A MX2020000636 A MX 2020000636A MX 2020000636 A MX2020000636 A MX 2020000636A MX 2020000636 A MX2020000636 A MX 2020000636A MX 2020000636 A MX2020000636 A MX 2020000636A
- Authority
- MX
- Mexico
- Prior art keywords
- synthetic proteins
- therapeutic uses
- disclosure relates
- proteins
- synthetic
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001131—Epidermal growth factor [EGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001134—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762533901P | 2017-07-18 | 2017-07-18 | |
| PCT/IB2018/000898 WO2019016597A2 (en) | 2017-07-18 | 2018-07-18 | SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000636A true MX2020000636A (es) | 2020-08-20 |
Family
ID=63857968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000636A MX2020000636A (es) | 2017-07-18 | 2018-07-18 | Proteinas sinteticas y usos terapeuticos de las mismas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12134662B2 (https=) |
| EP (1) | EP3655025A2 (https=) |
| JP (1) | JP7751357B2 (https=) |
| KR (1) | KR102903351B1 (https=) |
| CN (1) | CN111246878A (https=) |
| AU (1) | AU2018304957B2 (https=) |
| BR (1) | BR112020001045A2 (https=) |
| CA (1) | CA3070034A1 (https=) |
| IL (2) | IL300235A (https=) |
| MX (1) | MX2020000636A (https=) |
| RU (1) | RU2020106669A (https=) |
| WO (1) | WO2019016597A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3108236A1 (en) | 2018-08-07 | 2020-02-13 | In3Bio Ltd. | Methods and compositions for inhibition of egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors |
| CN114269792B (zh) * | 2019-06-25 | 2025-08-08 | 因斯瑞拜奥有限公司 | 稳定的嵌合合成蛋白及其治疗用途 |
| CN115379851A (zh) * | 2019-11-07 | 2022-11-22 | 因斯瑞拜奥有限公司 | 使用生长因子抗体与非酪氨酸靶向激酶抑制剂的组合的方法和组合物 |
| CA3236522A1 (en) | 2021-10-28 | 2023-05-04 | In3Bio Ltd. | Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors |
| USD1055117S1 (en) | 2022-12-29 | 2024-12-24 | Samsung Electronics Co., Ltd. | Refrigerator |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3238190A (en) | 1963-10-23 | 1966-03-01 | Madaus & Co K G Fa Dr | Aescin recovery |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| CA2261433A1 (en) * | 1993-12-09 | 1995-06-10 | Belinda Sanchez Ramirez | Composition comprising autologous epidermal growth factor |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| JPH10147952A (ja) | 1996-11-18 | 1998-06-02 | Komatsu Ltd | ブルドーザのドージング装置 |
| CA2302522C (en) | 1997-08-29 | 2010-08-17 | Antigenics Llc | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
| PT1187629E (pt) | 1999-04-19 | 2005-02-28 | Glaxosmithkline Biolog Sa | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador |
| CU22999A1 (es) | 2001-12-04 | 2004-10-12 | Centro Inmunologia Molecular | Método de tratamiento de enfermedades malignas e infecciosas crónicas |
| JP3855886B2 (ja) | 2002-08-29 | 2006-12-13 | トヨタ自動車株式会社 | 路面状態変化推定装置およびこれを搭載する自動車 |
| JP4623625B2 (ja) * | 2003-07-24 | 2011-02-02 | 株式会社AMBiS | ヘテロ型５量体組換えワクチン |
| WO2007109673A2 (en) * | 2006-03-20 | 2007-09-27 | Stanford University | Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor |
| MX354902B (es) * | 2011-11-23 | 2018-03-23 | Bioven 3 Ltd | Proteínas recombinantes y sus usos terapéuticos. |
| EP2970409A2 (en) * | 2013-03-15 | 2016-01-20 | Bioven 3 Limited | Self-assembling synthetic proteins |
| US12595297B2 (en) * | 2015-05-12 | 2026-04-07 | In3Bio Ltd. | Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors |
| EP3345613B1 (en) * | 2015-09-01 | 2023-05-10 | Il Dong Pharmaceutical Co., Ltd. | Composition for use in treating cancer or an angiogenesis-related disease comprising a fusion protein of a tumor-penetrating peptide and an anti-vegf agent |
-
2018
- 2018-07-18 JP JP2020502422A patent/JP7751357B2/ja active Active
- 2018-07-18 US US16/631,690 patent/US12134662B2/en active Active
- 2018-07-18 CA CA3070034A patent/CA3070034A1/en active Pending
- 2018-07-18 BR BR112020001045-6A patent/BR112020001045A2/pt unknown
- 2018-07-18 WO PCT/IB2018/000898 patent/WO2019016597A2/en not_active Ceased
- 2018-07-18 KR KR1020207004272A patent/KR102903351B1/ko active Active
- 2018-07-18 IL IL300235A patent/IL300235A/en unknown
- 2018-07-18 AU AU2018304957A patent/AU2018304957B2/en active Active
- 2018-07-18 RU RU2020106669A patent/RU2020106669A/ru unknown
- 2018-07-18 MX MX2020000636A patent/MX2020000636A/es unknown
- 2018-07-18 EP EP18786382.4A patent/EP3655025A2/en active Pending
- 2018-07-18 CN CN201880053878.8A patent/CN111246878A/zh active Pending
-
2020
- 2020-01-15 IL IL272050A patent/IL272050B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7751357B2 (ja) | 2025-10-08 |
| IL300235A (en) | 2023-03-01 |
| KR102903351B1 (ko) | 2025-12-24 |
| IL272050B1 (en) | 2023-03-01 |
| US20210009716A1 (en) | 2021-01-14 |
| CA3070034A1 (en) | 2019-01-24 |
| JP2020527579A (ja) | 2020-09-10 |
| BR112020001045A2 (pt) | 2020-09-08 |
| IL272050A (en) | 2020-03-31 |
| IL272050B2 (en) | 2023-07-01 |
| WO2019016597A2 (en) | 2019-01-24 |
| EP3655025A2 (en) | 2020-05-27 |
| RU2020106669A (ru) | 2021-08-18 |
| US12134662B2 (en) | 2024-11-05 |
| WO2019016597A3 (en) | 2019-04-18 |
| AU2018304957A1 (en) | 2020-02-13 |
| AU2018304957B2 (en) | 2025-05-15 |
| KR20200029010A (ko) | 2020-03-17 |
| CN111246878A (zh) | 2020-06-05 |
| RU2020106669A3 (https=) | 2022-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| PH12018502429A1 (en) | Antibody molecules for cancer treatment | |
| WO2018190719A3 (en) | Anti-sirp alpha antibodies | |
| AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| MX2022007522A (es) | Anticuerpos anti-cd27. | |
| ZA201801083B (en) | Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
| PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
| PH12016501644A1 (en) | Binding proteins and methods of use thereof | |
| PH12016500137A1 (en) | Afucosylated anti-fgfr2iiib antibodies | |
| NZ631701A (en) | Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
| MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| MA40363A (fr) | Agents de liaison de rspo1 et leurs utilisations | |
| MX2021015922A (es) | Proteínas quiméricas sintéticas estabilizadas y sus usos terapéuticos. | |
| MA39718A (fr) | Compositions et méthodes d'utilisation de celles-ci | |
| HK1237265A1 (en) | Combination therapy compositions and methods for treating cancers |